Skip to main content
Clinical Trials/NCT02756286
NCT02756286
Completed
Not Applicable

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

Think Now Incorporated3 sites in 1 country258 target enrollmentJanuary 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Attention Deficit Hyperactivity Disorder
Sponsor
Think Now Incorporated
Enrollment
258
Locations
3
Primary Endpoint
NAT Slow Fluctuation Test and Retest to assess change for Test Replicability
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.

Detailed Description

The purpose of this study is to build upon the success the novel approach and software for analyzing electroencephalography (EEG) data to identify biomarkers of ADHD in adults by further refining the method. Then to test the ability of this new assessment tool to differentiate between adults with ADHD and healthy controls by comparing the classification accuracy of the metrics from the new tool to the classification accuracy of existing behavioral tests for ADHD.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
July 5, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gregory Simpson, Ph.D.

Founder and Chief Scientific Officer

Think Now Incorporated

Eligibility Criteria

Inclusion Criteria

  • Specific inclusion criteria for ADHD are:
  • meet established Diagnositic and Statistical Manual-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD
  • no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed with the Mini International Neuropsychiatric Interview (MINI).
  • able in the opinion of the investigator to complete all required study procedures.

Exclusion Criteria

  • Exclusion criteria for both groups are:
  • History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)
  • history of any general medical condition likely to require chronic use of medication with identified central nervous system (CNS) effects suspected to alter cognitive performance
  • history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness
  • serious oxygen deprivation
  • current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants
  • current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity)
  • current treatment with guanfacine.

Outcomes

Primary Outcomes

NAT Slow Fluctuation Test and Retest to assess change for Test Replicability

Time Frame: A single measurement is made for each individual at DAY 1 - the time of the brain wave (EEG) test; and a single measure is made again in each individual at least 30 days later (DAY 2) to identify any differences, to assess replicability of the measure.

The NAT EEG test simultaneously generates 2 EEG values and 1 behavioral value that are used together as an assessment metric for ADHD. This is a one-time measure to assess its magnitude in ADHD vs Control.

Study Sites (3)

Loading locations...

Similar Trials